ArticleScientific reports2026
Therapeutic effects of IGF-2 on NMOSD by inhibiting astrocyte apoptosis through modulation of the IGF-1R/PI3K/AKT signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease characterized by the presence of antibodies specific to the aquaporins 4 (AQP4) protein. The complexity of its pathogenesis poses significant challenges to treatment, which remains both limited and costly. Consequently, there is an urgent need to elucidate the pathogenesis of NMOSD and to develop novel therapeutic strategies. Here, through a proteomic screen of serum from AQP4-IgG-positive NMOSD patients and a control cohort, we observed a significant downregulation of Insulin-like growth factor 2 (IGF-2) in the serum of AQP4-IgG-positive NMOSD patients and correlated with disease severity. Injecting adenovirus overexpressing IGF-2 into the brains of NMOSD mice reduced microglia, neuroinflammation, and brain injury. Both in vivo and in vitro experiments show IGF-2 activates the IGF-1R/PI3K/AKT pathway, reducing apoptosis and inflammation. These findings highlight IGF-2 as a promising target for NMOSD diagnosis and treatment, offering new insights into disease mechanisms and potential interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.